Connect with us

Published

on

A man wearing Abbott’s Lingo biosensor.

Courtesy of Abbott

Abbott Laboratories announced Thursday its over-the-counter continuous glucose monitor Lingo is available in the U.S. starting at $49. 

Lingo is part of an emerging class of consumer-friendly biosensors that people can use to learn how their bodies respond to food, exercise, sleep and stress. These devices, called continuous glucose monitors, are small sensors that stick through the skin to measure real-time glucose levels. Glucose is a sugar molecule that comes from food, and it’s the body’s main energy source.

Continuous glucose monitors have served as tools for patients with diabetes, but Lingo is not intended for diabetes management. Instead, it’s designed for adults who do not take insulin and want to “improve their overall health and wellness,” according to a release. 

Everyone’s glucose levels fluctuate, but consistently high levels can cause more serious health problems like metabolic disease, insulin resistance and heart disease, Abbott said. The company argues Lingo can educate users about existing habits and help them learn to manage their glucose in healthier ways.

“That’s really the goal, is to not only see and understand what’s happening inside your body, but to be able to improve on that, to be able to build these healthy habits that drive those changes,” Ben Fohner, the director of Abbott’s Lingo app, told CNBC in an interview. 

Abbott already offers continuous glucose monitors for diabetes patients in the U.S., so the company is looking to break into an entirely new market with Lingo. About 1 in 3 Americans have prediabetes, for instance, but these patients typically don’t qualify for prescriptions or insurance coverage for the monitors. 

Now, they can pay for the sensors out of pocket without a prescription. Users can buy one sensor online for $49, two sensors for $89 or six sensors for $249, Abbott said. Each sensor is worn on the upper arm for up to 14 days. 

Olivier Ropars, Abbott’s divisional vice president of Lingo, said the company decided to offer three different pricing options so curious consumers won’t feel intimidated by a lengthy commitment. A customer can opt to buy just one sensor to try for a couple of weeks.

“We want to make it as accessible and affordable as possible,” Ropars told CNBC in an interview. 

Abbott’s competitor, Dexcom, is also eyeing the prediabetes market. The company released its over-the-counter continuous glucose monitor geared toward this demographic in late August. Dexcom’s device is called Stelo, and is available in the U.S. for $89 a month. Patients with Type 2 diabetes who do not take insulin can also use it, the company said.

The U.S. Food and Drug Administration approved Dexcom’s Stelo in March, and it cleared two over-the-counter continuous glucose monitoring systems from Abbott in June. One of Abbott’s systems was Lingo, and the second system, called Libre Rio, is intended for patients with Type 2 diabetes who do not take insulin.

Though Type 2 patients who are not taking insulin could technically use Lingo, Ropars said Abbott’s recommendation is to primarily use Libre Rio since it is specifically designed for them. The company declined to share when Libre Rio will be available.

The Lingo app

Abbott’s Lingo app.

Courtesy of Abbott

Like many continuous glucose monitors, Lingo transmits data wirelessly to an app. When users open it, they’ll see a real-time reading of their glucose data that’s updated every minute. 

Those glucose readings are plotted on a graph, which includes a shaded area to indicate a “healthy range.” Fohner said Abbott’s clinical team defines this range as 140 milligrams per deciliter to 70 milligrams per deciliter.

One of Abbott’s primary goals is to help Lingo users learn about glucose spikes, which occur when the amount of sugar present in the bloodstream rapidly increases and then decreases. Glucose spikes commonly occur after eating. 

Spikes can push a user’s glucose reading above the healthy range, but they can also occur within the healthy range. Limiting spikes and improving glucose management overall can help users improve their sleep and mood, manage their weight, and be proactive about their future health, Abbott said.

To help users conceptualize the impact of their spikes, Abbott created a metric called the “Lingo Count.” It’s an algorithm that assigns a numeric value to each glucose spike, and it’s supposed to represent how significant the impact is. Over each day, users have a target Lingo Count that they want to aim to stay below. 

Abbott’s Lingo app.

Courtesy of Abbott

Users can see this data represented on a second, more interactive glucose graph when they scroll down Lingo’s home page. A number will appear in the shaded area beneath a spike, which represents the Lingo Count for that spike. 

“It’s unique to Lingo, but really that number is an indicator and a function of, how high did your spike go, how long did it last, and what was the impact that that spike had on your body,” Fohner said. 

Users can analyze Lingo Count data and see how they are doing over time, as well as what time of day they tend to experience the most dramatic spikes. They can also participate in challenges and access educational resources to learn how to reduce those spikes.  

Ropars said metabolism doesn’t change overnight, and everyone’s bodies work differently. He said Lingo can serve as a window into how and why a user’s glucose levels vary. But the real value of Lingo, Ropars said, is the support it can offer users as they try to establish healthy habits.

“A lot of our products today are geared toward helping people that are experiencing a chronic disease or sickness and trying to get back on track,” he said. “Here, this is the first time we’re doing a product that is helping people, improving their daily life, taking control of their health before they get sick”

Don’t miss these insights from CNBC PRO

Continue Reading

Technology

Motive, an Alphabet-backed fleet management software company, files for IPO

Published

on

By

Motive, an Alphabet-backed fleet management software company, files for IPO

Direxion signage at the New York Stock Exchange (NYSE) in New York, US, on Monday, Dec. 22, 2025. The holiday-shortened week started with gains in stocks amid a broad advance that saw a continuation of the bullish momentum on Wall Street.

Michael Nagle | Bloomberg | Getty Images

Motive, a company with software for managing corporate trucks and drivers, on Tuesday filed for an initial public offering on the New York Stock Exchange under the symbol “MTVE.”

The paperwork puts Motive among a fast-growing group of tech companies looking to go public in 2026. Anthropic, OpenAI and SpaceX have all reportedly considered making their shares widely available for trading next year.

Motive is smaller, reporting a $62.7 million net loss on $115.8 million in revenue in the third quarter. The loss widened from $41.3 million in the same quarter of 2024, while revenue grew about 23% year over year. The company had almost 100,000 clients at the end of September.

Ryan Johns, Obaid Khan and Shoaib Makani started Motive in 2013, originally under the name Keep Truckin. Makani, the CEO, is Khan’s brother-in-law.

Investors include Alphabet’s GV, Base10 Partners, Greenoaks, Index Ventures, Kleiner Perkins and Scale Venture Partners.

Motive’s AI Dashcam device for detecting unsafe driving “has prevented 170,000 collisions and saved 1,500 lives on our roads,” Makani wrote in a letter to investors. Most revenue comes from subscriptions, although Motive does sell replacement hardware and professional services.

The San Francisco company changed its name to Motive in 2022, and as of Sept. 30, it employed 4,508 people. Motive employs 400 full-time data annotators who apply labels that are meant to enhance artificial intelligence models.

Motive has ongoing patent-infringement litigation with competitor Samsara, which went public in 2021 and today has a $22 billion market capitalization.

WATCH: AI IPO boom next year? The changing 2026 IPO landscape

AI IPO boom next year? The changing 2026 IPO landscape

Continue Reading

Technology

Why an analyst sees Meta shares getting back to record highs – plus, another tariff reprieve

Published

on

By

Why an analyst sees Meta shares getting back to record highs – plus, another tariff reprieve

Continue Reading

Technology

U.S. pushes additional tariffs on Chinese chips to June 2027

Published

on

By

U.S. pushes additional tariffs on Chinese chips to June 2027

A silicon wafer with chips etched into is seen as U.S. Vice President Kamala Harris tours a site where Applied Materials plans to build a research facility, in Sunnyvale, California, U.S., May 22, 2023.

Pool | Reuters

The U.S. will increase tariffs on Chinese semiconductor imports in June 2027, at a rate to be determined at least a month in advance, the Trump administration said in a Federal Register filing on Tuesday.

But in the meantime, the initial tariff rate on semiconductor imports from China will be zero for 18 months, according to the filing from the Office of the U.S. Trade Representative.

As part of an investigation that kicked off a year ago, the agency found that China is engaging in unfair trade practices in the industry.

“For decades, China has targeted the semiconductor industry for dominance and has employed increasingly aggressive and sweeping non-market policies and practices in pursuing dominance of the sector,” the office said in the filing.

The decision to delay new tariffs for at least 18 months signals that the Trump administration is seeking to cool any trade hostilities between the U.S. and China.

Read more CNBC tech news

Additional tariffs could also become a bargaining chip if future talks break down.

U.S. President Donald Trump and Chinese President Xi Jinping reached a truce in the so-called trade war in October, as part of a deal that included the U.S. slashing some tariffs and China allowing exports of rare earth metals.

The USTR’s Tuesday filing states that tariffs will increase on June 23, 2027.

The notice is the next step in a process focusing on older chips that started during the Biden administration under Section 301 of the Trade Act.

The new 2027 date gives clarity to American firms that have said they are closely watching how U.S. tariffs could affect their businesses or supply chains.

The tariffs are separate from other duties threatened by the Trump administration on Chinese chip imports under Section 232 of the law.

EUV machines are key source of leverage for U.S. over China in AI race, says CSIS’s Gregory Allen

Continue Reading

Trending